189 related articles for article (PubMed ID: 36951942)
1. IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models.
Jaspers JE; Khan JF; Godfrey WD; Lopez AV; Ciampricotti M; Rudin CM; Brentjens RJ
J Clin Invest; 2023 May; 133(9):. PubMed ID: 36951942
[TBL] [Abstract][Full Text] [Related]
2. Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth.
Chen X; Amar N; Zhu Y; Wang C; Xia C; Yang X; Wu D; Feng M
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554616
[TBL] [Abstract][Full Text] [Related]
3. TREM1/DAP12 based novel multiple chain CAR-T cells targeting DLL3 show robust anti-tumour efficacy for small cell lung cancer.
Nie F; Chen Y; Hu Y; Huang P; Shi X; Cai J; Qiu M; Wang E; Lu K; Sun M
Immunology; 2024 Mar; ():. PubMed ID: 38469682
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer.
Zhang Y; Tacheva-Grigorova SK; Sutton J; Melton Z; Mak YSL; Lay C; Smith BA; Sai T; Van Blarcom T; Sasu BJ; Panowski SH
Clin Cancer Res; 2023 Mar; 29(5):971-985. PubMed ID: 36692420
[TBL] [Abstract][Full Text] [Related]
5. CAR NK-92 cells targeting DLL3 kill effectively small cell lung cancer cells in vitro and in vivo.
Liu M; Huang W; Guo Y; Zhou Y; Zhi C; Chen J; Li J; He J; Lian H; Zhou J; Ye X; Hu Y; Hu H; Liu Z; Huang J; Lin L; Cai M; Wang X; Huang J; Zhang Z; Zhu K; Zhao Q; Cao B
J Leukoc Biol; 2022 Oct; 112(4):901-911. PubMed ID: 35088475
[TBL] [Abstract][Full Text] [Related]
6. A Bispecific DLL3/CD3 IgG-Like T-Cell Engaging Antibody Induces Antitumor Responses in Small Cell Lung Cancer.
Hipp S; Voynov V; Drobits-Handl B; Giragossian C; Trapani F; Nixon AE; Scheer JM; Adam PJ
Clin Cancer Res; 2020 Oct; 26(19):5258-5268. PubMed ID: 32554516
[TBL] [Abstract][Full Text] [Related]
7. AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer.
Giffin MJ; Cooke K; Lobenhofer EK; Estrada J; Zhan J; Deegen P; Thomas M; Murawsky CM; Werner J; Liu S; Lee F; Homann O; Friedrich M; Pearson JT; Raum T; Yang Y; Caenepeel S; Stevens J; Beltran PJ; Canon J; Coxon A; Bailis JM; Hughes PE
Clin Cancer Res; 2021 Mar; 27(5):1526-1537. PubMed ID: 33203642
[TBL] [Abstract][Full Text] [Related]
8. Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer.
Rudin CM; Reck M; Johnson ML; Blackhall F; Hann CL; Yang JC; Bailis JM; Bebb G; Goldrick A; Umejiego J; Paz-Ares L
J Hematol Oncol; 2023 Jun; 16(1):66. PubMed ID: 37355629
[TBL] [Abstract][Full Text] [Related]
9. Near infrared photoimmunotherapy targeting DLL3 for small cell lung cancer.
Isobe Y; Sato K; Nishinaga Y; Takahashi K; Taki S; Yasui H; Shimizu M; Endo R; Koike C; Kuramoto N; Yukawa H; Nakamura S; Fukui T; Kawaguchi K; Chen-Yoshikawa TF; Baba Y; Hasegawa Y
EBioMedicine; 2020 Feb; 52():102632. PubMed ID: 31981983
[TBL] [Abstract][Full Text] [Related]
10. Targeting CDH17 with Chimeric Antigen Receptor-Redirected T Cells in Small Cell Lung Cancer.
Tian W; Zhao J; Wang W
Lung; 2023 Oct; 201(5):489-497. PubMed ID: 37823901
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of the DLL3/CD3 bispecific T-cell engager BI 764532 in DLL3-positive small-cell lung cancer and neuroendocrine carcinomas.
Wermke M; Felip E; Gambardella V; Kuboki Y; Morgensztern D; Hamed ZO; Liu M; Studeny M; Owonikoko TK
Future Oncol; 2022 Aug; 18(24):2639-2649. PubMed ID: 35815644
[TBL] [Abstract][Full Text] [Related]
12. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
[TBL] [Abstract][Full Text] [Related]
13. Comparison of four DLL3 antibodies performance in high grade neuroendocrine lung tumor samples and cell cultures.
Brcic L; Kuchler C; Eidenhammer S; Pabst D; Quehenberger F; Gazdar AF; Popper H
Diagn Pathol; 2019 May; 14(1):47. PubMed ID: 31109352
[TBL] [Abstract][Full Text] [Related]
14. Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer.
Reppel L; Tsahouridis O; Akulian J; Davis IJ; Lee H; Fucà G; Weiss J; Dotti G; Pecot CV; Savoldo B
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35022195
[TBL] [Abstract][Full Text] [Related]
15. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
Front Immunol; 2021; 12():665970. PubMed ID: 34475869
[TBL] [Abstract][Full Text] [Related]
16. A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.
Saunders LR; Bankovich AJ; Anderson WC; Aujay MA; Bheddah S; Black K; Desai R; Escarpe PA; Hampl J; Laysang A; Liu D; Lopez-Molina J; Milton M; Park A; Pysz MA; Shao H; Slingerland B; Torgov M; Williams SA; Foord O; Howard P; Jassem J; Badzio A; Czapiewski P; Harpole DH; Dowlati A; Massion PP; Travis WD; Pietanza MC; Poirier JT; Rudin CM; Stull RA; Dylla SJ
Sci Transl Med; 2015 Aug; 7(302):302ra136. PubMed ID: 26311731
[TBL] [Abstract][Full Text] [Related]
17. DLL3-guided therapies in small-cell lung cancer: from antibody-drug conjugate to precision immunotherapy and radioimmunotherapy.
Su PL; Chakravarthy K; Furuya N; Brownstein J; Yu J; Long M; Carbone D; Li Z; He K
Mol Cancer; 2024 May; 23(1):97. PubMed ID: 38730427
[TBL] [Abstract][Full Text] [Related]
18. Expression of delta-like protein 3 is reproducibly present in a subset of small cell lung carcinomas and pulmonary carcinoid tumors.
Xie H; Boland JM; Maleszewski JJ; Aubry MC; Yi ES; Jenkins SM; Koepplin JW; Terra SBSP; Mansfield AS; Roden AC
Lung Cancer; 2019 Sep; 135():73-79. PubMed ID: 31447005
[TBL] [Abstract][Full Text] [Related]
19. DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms.
Yao J; Bergsland E; Aggarwal R; Aparicio A; Beltran H; Crabtree JS; Hann CL; Ibrahim T; Byers LA; Sasano H; Umejiego J; Pavel M
Oncologist; 2022 Nov; 27(11):940-951. PubMed ID: 35983951
[TBL] [Abstract][Full Text] [Related]
20. Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy.
Zhang Z; Jiang J; Wu X; Zhang M; Luo D; Zhang R; Li S; He Y; Bian H; Chen Z
Front Med; 2019 Feb; 13(1):57-68. PubMed ID: 30721445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
